AJANTPHARM
AJANTA PHARMA LIMITED
Each stock's 10,000-path forecast, rendered as light.
AJANTA PHARMA LIMITED (AJANTPHARM) Stock Analysis & Case Study
Is AJANTPHARM a good buy? The data-driven verdict.
AJANTA PHARMA LIMITED (AJANTPHARM) trades at ₹3,489,on the numbers it worth a closer look, a Downstox Snapshot Score of 58/100.
On the numbers, AJANTA PHARMA LIMITED (AJANTPHARM) worth a closer look, a Downstox Snapshot Score of 58/100, weighing premium at 38.4× earnings, ROE of 27.1%, a 60% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
AJANTPHARM fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How AJANTPHARM ranks against the 2,373 companies in our screener
- AJANTPHARM's market cap of 43,601 Cr ranks in the 91st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AJANTPHARM's book value of ₹362 ranks in the 85th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AJANTPHARM's promoter holding of 63.5% ranks in the 59th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AJANTPHARM's 3-year profit (PAT) growth of 24.0% ranks in the 62nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AJANTPHARM's 3-year revenue growth of 13.0% ranks in the 58th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AJANTPHARM's debt-to-equity ratio of 0.06x is lower than 84% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is AJANTPHARM overvalued? AJANTPHARM P/E vs peers
AJANTPHARM trades at 38.4× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
AJANTPHARM share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of AJANTPHARM history (10%/yr drift, 32%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| AJANTPHARM 2027 | ₹2,507 | ₹3,774 | ₹5,682 | +8% |
| AJANTPHARM 2028 | ₹2,285 | ₹4,083 | ₹7,297 | +17% |
| AJANTPHARM 2029 | ₹2,175 | ₹4,417 | ₹8,969 | +27% |
| AJANTPHARM 2030 | ₹2,105 | ₹4,778 | ₹10,842 | +37% |
| AJANTPHARM 2031 | ₹2,090 | ₹5,168 | ₹12,777 | +48% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability AJANTPHARM goes up, or doubles?
The bull case for AJANTPHARM
- AJANTPHARM's return on equity of 27.1% ranks in the 92nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AJANTPHARM's return on capital employed of 34.5% ranks in the top 5% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹8,969.
The bear case & risks
- AJANTPHARM's P/E of 38.4x is lower than 35% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A steep 9.6× price-to-book means most of the value is intangible/expectations, not assets on the books.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹2,175.
AJANTPHARM volatility & expected range, how bumpy is the ride?
Over the last 9.8 years AJANTPHARM compounded at 10%/year with annualized volatility of 32%. That volatility implies a 1-year 80% range of ₹2,507-₹5,682, the honest backbone behind any single price target.
AJANTPHARM price forecast, the full 60-month probability fan
AJANTPHARM price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds AJANTPHARM hits common targets within the simulated horizon?
Full multi-horizon detail on the AJANTPHARM price target & forecast page.
AJANTPHARM Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. AJANTPHARM scores 6/8, mixed financial health.
AJANTPHARM MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy AJANTPHARM with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 29.09% | 3.4× |
| Zerodha | 29.07% | 3.4× |
| Groww | 29.17% | 3.4× |
| DhanCHEAPEST | 29.07% | 3.4× |
| Kotak Neo | 30.03% | 3.3× |
| Paytm Money | 29.26% | 3.4× |
| Pocketful | 29.23% | 3.4× |
| Anand Rathi | 29.07% | 3.4× |
| Bajaj Broking | 31.00% | 3.2× |
| Share India | 29.15% | 3.4× |
Compare every broker on the AJANTPHARM MTF page.
About AJANTA PHARMA LIMITED: sector, index & market-cap context
AJANTA PHARMA LIMITED (AJANTPHARM) is a mid-cap NSE-listed company, and a constituent of the Nifty 500 index, with a market capitalisation of ₹43,601 Cr. See more stocks on our screener.
How the AJANTPHARM Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of AJANTA PHARMA LIMITED's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
AJANTPHARM analysis, FAQs
Is AJANTA PHARMA LIMITED (AJANTPHARM) a good buy?
On the numbers, AJANTA PHARMA LIMITED (AJANTPHARM) worth a closer look, a Downstox Snapshot Score of 58/100, weighing premium at 38.4× earnings, ROE of 27.1%, a 60% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is AJANTPHARM overvalued or undervalued?
AJANTPHARM trades at 38.4× earnings, premium versus the ~22× long-run Nifty average.
What is the AJANTPHARM share price target for 2031?
AJANTPHARM's probability-weighted 2031 median target is ₹5,168, with an 80% range of ₹2,090-₹12,777 (10,000-path Monte-Carlo).
What is the probability AJANTPHARM doubles in 5 years?
The modelled probability of AJANTPHARM reaching ₹6,978 (2×) within 5 years is 34%.
What is the bull case for AJANTPHARM?
AJANTPHARM's return on equity of 27.1% ranks in the 92nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. AJANTPHARM's return on capital employed of 34.5% ranks in the top 5% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in AJANTPHARM?
AJANTPHARM's P/E of 38.4x is lower than 35% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A steep 9.6× price-to-book means most of the value is intangible/expectations, not assets on the books.